Beam Therapeutics Announces Updated Clinical Data From Its Phase 1/2 Trial Evaluating BEAM-302 For Alpha-1 Antitrypsin Deficiency; BEAM-302 Continues To Demonstrate Potential As One-Time Treatment For Both Lung And Liver Manifestations Of AATD

With Up to 18 Months Follow-Up, Data Show Long-Term Durability of In Vivo Correction of Disease-causing Mutation with Single Dose of BEAM-302

Treatment with BEAM-302 Increased Total and Functional AAT and Decreased Neutrophil Elastase Activity in Circulation

BEAM-302 Led to Reduction in Circulating Mutant Z-AAT and Corresponding Decrease in Toxic Circulating Z-polymers

Safety Profile of BEAM-302 Remains Consistent with LNP-based Therapies

Dosing Underway in Global Pivotal Cohort Designed to Support Potential U.S. Accelerated Approval

Beam to Host Investor Webcast Today, September 8, 2026, at 7:00 a.m. ET